Clinical Trials Browser

Phase 1 × Interventional × tepotinib × Clear all

NCT05782361 2026-04-24

POTENT

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05120960 2024-04-17

A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors

Phase 1 Withdrawn

Brain Neoplasms

NCT03492437 2023-08-07

Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate

Phase 1 Completed

20 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT03531762 2023-07-28

Effect of a Proton Pump Inhibitor on the PK of Tepotinib

Phase 1 Completed

12 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT01014936 2022-08-24

First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors

Phase 1 Completed

149 enrolled 41 charts

Other solid neoplasm

Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available